Quarterly report
Open the filing on sec.gov
TG Therapeutics, Inc. (TGTX)
Nasdaq: TGTX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 1996
Grade7.3
◀ Past 6.5● Present 8.6▶ Future 6.2
The companyfiscal 2025, as filed
Revenue$616M+87.3%
Net income$447M+1812.4%
Earnings per share$2.77+1746.7%
Operating cash flow-$24.8M+38.9%
Cash$79.1M-56.0%
Debt$246M+0.5%
Shareholders’ equity$648M+191.4%
Shares, diluted161.4M+0.7%
Return on equity69.0%
The recordfrom its filings
Filings in 202628
Newest filingNov 9 · 10-Q
Annual reportFeb 27, 2026
Quarterly reportNov 9, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$400,000
Insider buys, 12 months$0.00
Patents granted8
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $898MNet income $106MCash from operations $86.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.